HONG KONG – Samsung Bioepis Co. Ltd. has received approval in both South Korea and Europe for its Herceptin biosimilar. Known as Samfenet in South Korea and as Ontruzant in Europe, it marks the first Herceptin biosimilar to be approved by the European Commission.